Clinical Trials
259
15 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1981
Active, not recruiting
3
1.2%
Completed
129
49.8%
Enrolling By Invitation
1
0.4%
Not yet recruiting
11
4.3%
Recruiting
35
13.5%
Suspended
2
0.8%
Temporarily Not Available
1
0.4%
Terminated
3
1.2%
Unknown
70
27.0%
Withdrawn
4
1.5%
No approval data available
- Gene Solutions has launched SPOT-MAS, an AI-powered multi-cancer early detection platform in Taiwan, integrating multi-omics cell-free DNA analysis to bridge gaps in traditional cancer screening. - The technology analyzes genetic, epigenetic, and fragmentomic features using AI algorithms to enhance early detection accuracy and predict tumor location more precisely than single biomarker approaches. - Taiwan medical experts emphasize the urgent clinical need, noting that early cancer detection can result in five-year survival rates several times higher than late-stage detection. - The launch represents a significant step toward making multi-cancer screening accessible beyond premium healthcare, with plans for cross-sector collaboration to establish comprehensive cancer prevention frameworks.
- Far Eastern Memorial Hospital in New Taipei City administered Taiwan's first dose of Kisunla (donanemab), a new Alzheimer's drug that targets underlying disease causes rather than just symptoms. - The monoclonal antibody treatment, developed by Eli Lilly, was given to an 83-year-old woman and represents a breakthrough approach to reducing amyloid plaques in the brain. - Both Kisunla and Leqembi require 12-18 months of treatment to significantly reduce amyloid accumulation, with fewer than 100,000 of Taiwan's 350,000 dementia patients eligible for these therapies. - While promising, experts caution these drugs are not cures and require ongoing monitoring, with long-term effectiveness and side effects still under evaluation.
